This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kyle, A. H. Articles by Minchinton, A. I. Search for Related Content PubMed PubMed Citation Articles by Kyle, A. H. Articles by Minchinton, A. I.

Tumor Distribution of Bromodeoxyuridine-labeled Cells Is Strongly Dose Dependent¹

Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z 1L3 Canada

Bromodeoxyuridine (BrdUrd) is used extensively to measure the fraction of proliferating cells in tumors. Unlike endogenous markers of proliferation such as proliferating cell nuclear antigen (PCNA) and Ki-67, BrdUrd is exogenously administered and reaches the tumor via vasculature where it must then diffuse throughout the tissue to label S-phase cells. In this study, we examine the dose dependence of BrdUrd on the tumor distribution of labeled cells in histological sections. Analysis of the distribution of labeled cells in SiHa tumor xenografts showed that a dose between 400 and 1000 mg/kg was required to label cells 150 µm from blood vessels, approaching the border of necrosis. Lower doses resulted in only the cells close to blood vessels being labeled. Interestingly, cells residing furthest from blood vessels still labeled albeit at half the level of cells situated proximal to the tumor vasculature. Results were compared with the penetration of BrdUrd seen in vitro using multilayered cell culture (MCC), a three-dimensional tissue culture model of solid tumors. Using MCC, an exposure of 100 µM BrdUrd for 1 h was required for labeling of S-phase cells 150 µm into the tissue, whereas cells adjacent to the edge of the tissue could be adequately labeled with just 5 µM BrdUrd for 1 h. The area under the curve for a 100 mg/kg BrdUrd dose in mice was found to be 30 µM·h.

This article has been cited by other articles:

				P. D. Ottewell, B. Deux, H. Monkkonen, S. Cross, R. E. Coleman, P. Clezardin, and I. Holen Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo Clin. Cancer Res., July 15, 2008; 14(14): 4658 - 4666. [Abstract] [Full Text] [PDF]

				A. H. Kyle, L. A. Huxham, D. M. Yeoman, and A. I. Minchinton Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2804 - 2810. [Abstract] [Full Text] [PDF]

				L. A. Huxham, A. H. Kyle, J. H. E. Baker, L. K. Nykilchuk, and A. I. Minchinton Microregional Effects of Gemcitabine in HCT-116 Xenografts Cancer Res., September 15, 2004; 64(18): 6537 - 6541. [Abstract] [Full Text] [PDF]

				A. H. Kyle, L. A. Huxham, A. S. J. Chiam, D. H. Sim, and A. I. Minchinton Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture Cancer Res., September 1, 2004; 64(17): 6304 - 6309. [Abstract] [Full Text] [PDF]